NKTR Nektar Therapeutics
Nektar Therapeutics (NKTR) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 86% planned / 14% discretionary
Largest single sale: $397.7K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| ROBIN HOWARD W | President & CEO | Sell | 418 | $71.98 | $30.1K | 54,627 −0.8% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell | 186 | $71.98 | $13.4K | 9,570 −1.9% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell 10b5-1 | 5,681 | $70.00 | $397.7K | 9,756 −36.8% of holding | |
| ROBIN HOWARD W 2 fills | President & CEO | Sell 10b5-1 | 10,000 | $61.19 | $611.9K | 59,545 −14.4% of holding | |
| ROBIN HOWARD W 2 fills | President & CEO | Sell 10b5-1 | 10,000 | $60.32 | $603.2K | 69,742 −12.5% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell 10b5-1 | 5,538 | $60.71 | $336.2K | 15,437 −26.4% of holding | |
| ROBIN HOWARD W | President & CEO | Sell | 444 | $65.51 | $29.1K | 75,045 −0.6% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell | 199 | $65.51 | $13.0K | 20,975 −0.9% of holding | |
| ROBIN HOWARD W | President & CEO | Sell | 423 | $73.00 | $30.9K | 75,489 −0.6% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell | 180 | $73.00 | $13.1K | 21,174 −0.8% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell 10b5-1 | 3,867 | $35.67 | $137.9K | 21,354 −15.3% of holding | |
| ROBIN HOWARD W | President & CEO | Sell | 2,207 | $54.28 | $119.8K | 54,245 −3.9% of holding | |
| Zalevsky Jonathan | Chief R&D Officer | Sell | 1,157 | $54.28 | $62.8K | 18,971 −5.7% of holding | |
| Wilson Mark Andrew | Chief Legal Officer | Sell | 630 | $54.28 | $34.2K | 21,585 −2.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.